Re: Cetuximab therapy and symptomatic hypomagnesemia

J Natl Cancer Inst. 2005 Dec 7;97(23):1791-2. doi: 10.1093/jnci/dji412.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Cetuximab
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / metabolism
  • Erlotinib Hydrochloride
  • Gefitinib
  • Humans
  • Magnesium / blood*
  • Magnesium Deficiency / blood
  • Magnesium Deficiency / chemically induced*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Magnesium
  • Cetuximab
  • Gefitinib